RxDB
ICD-9-CM Codes ICD-9-PCS Codes

995.29 - Unspecified adverse effect of other drug, medicinal and biological substance

Overview

GEM Conversion to ICD-10 CM

Fs: 10000 – Adverse effect of penicillins, initial encounter
Fs: 10000 – Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter
Fs: 10000 – Adverse effect of chloramphenicol group, initial encounter
Fs: 10000 – Adverse effect of macrolides, initial encounter
Fs: 10000 – Adverse effect of tetracyclines, initial encounter
Fs: 10000 – Adverse effect of aminoglycosides, initial encounter
Fs: 10000 – Adverse effect of rifampicins, initial encounter
Fs: 10000 – Adverse effect of antifungal antibiotics, systemically used, initial encounter
Fs: 10000 – Adverse effect of other systemic antibiotics, initial encounter
Fs: 10000 – Adverse effect of unspecified systemic antibiotic, initial encounter
Fs: 10000 – Adverse effect of sulfonamides, initial encounter
Fs: 10000 – Adverse effect of antimycobacterial drugs, initial encounter
Fs: 10000 – Adverse effect of antimalarials and drugs acting on other blood protozoa, initial encounter
Fs: 10000 – Adverse effect of other antiprotozoal drugs, initial encounter
Fs: 10000 – Adverse effect of anthelminthics, initial encounter
Fs: 10000 – Adverse effect of antiviral drugs, initial encounter
Fs: 10000 – Adverse effect of other specified systemic anti-infectives and antiparasitics, initial encounter
Fs: 10000 – Adverse effect of unspecified systemic anti-infective and antiparasitic, initial encounter
Fs: 10000 – Adverse effect of glucocorticoids and synthetic analogues, initial encounter
Fs: 10000 – Adverse effect of thyroid hormones and substitutes, initial encounter
Fs: 10000 – Adverse effect of antithyroid drugs, initial encounter
Fs: 10000 – Adverse effect of oral contraceptives, initial encounter
Fs: 10000 – Adverse effect of other estrogens and progestogens, initial encounter
Fs: 10000 – Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, initial encounter
Fs: 10000 – Adverse effect of androgens and anabolic congeners, initial encounter
Fs: 10000 – Adverse effect of unspecified hormones and synthetic substitutes, initial encounter
Fs: 10000 – Adverse effect of anterior pituitary [adenohypophyseal] hormones, initial encounter
Fs: 10000 – Adverse effect of other hormones and synthetic substitutes, initial encounter
Fs: 10000 – Adverse effect of unspecified hormone antagonists, initial encounter
Fs: 10000 – Adverse effect of other hormone antagonists, initial encounter
Fs: 10000 – Adverse effect of aspirin, initial encounter
Fs: 10000 – Adverse effect of salicylates, initial encounter
Fs: 10000 – Adverse effect of 4-Aminophenol derivatives, initial encounter
Fs: 10000 – Adverse effect of pyrazolone derivatives, initial encounter
Fs: 10000 – Adverse effect of propionic acid derivatives, initial encounter
Fs: 10000 – Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter
Fs: 10000 – Adverse effect of antirheumatics, not elsewhere classified, initial encounter
Fs: 10000 – Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter
Fs: 10000 – Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, initial encounter
Fs: 10000 – Adverse effect of opium, initial encounter
Fs: 10000 – Adverse effect of other opioids, initial encounter
Fs: 10000 – Adverse effect of methadone, initial encounter
Fs: 10000 – Adverse effect of other synthetic narcotics, initial encounter
Fs: 10000 – Adverse effect of cocaine, initial encounter
Fs: 10000 – Adverse effect of unspecified narcotics, initial encounter
Fs: 10000 – Adverse effect of other narcotics, initial encounter
Fs: 10000 – Adverse effect of cannabis (derivatives), initial encounter
Fs: 10000 – Adverse effect of unspecified psychodysleptics [hallucinogens], initial encounter
Fs: 10000 – Adverse effect of other psychodysleptics [hallucinogens], initial encounter
Fs: 10000 – Adverse effect of therapeutic gases, initial encounter
Fs: 10000 – Adverse effect of hydantoin derivatives, initial encounter
Fs: 10000 – Adverse effect of iminostilbenes, initial encounter
Fs: 10000 – Adverse effect of succinimides and oxazolidinediones, initial encounter
Fs: 10000 – Adverse effect of barbiturates, initial encounter
Fs: 10000 – Adverse effect of benzodiazepines, initial encounter
Fs: 10000 – Adverse effect of mixed antiepileptics, initial encounter
Fs: 10000 – Adverse effect of other antiepileptic and sedative-hypnotic drugs, initial encounter
Fs: 10000 – Adverse effect of unspecified antiepileptic and sedative-hypnotic drugs, initial encounter
Fs: 10000 – Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, initial encounter
Fs: 10000 – Adverse effect of tricyclic antidepressants, initial encounter
Fs: 10000 – Adverse effect of tetracyclic antidepressants, initial encounter
Fs: 10000 – Adverse effect of monoamine-oxidase-inhibitor antidepressants, initial encounter
Fs: 10000 – Adverse effect of unspecified antidepressants, initial encounter
Fs: 10000 – Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, initial encounter
Fs: 10000 – Adverse effect of selective serotonin reuptake inhibitors, initial encounter
Fs: 10000 – Adverse effect of other antidepressants, initial encounter
Fs: 10000 – Adverse effect of phenothiazine antipsychotics and neuroleptics, initial encounter
Fs: 10000 – Adverse effect of butyrophenone and thiothixene neuroleptics, initial encounter
Fs: 10000 – Adverse effect of unspecified antipsychotics and neuroleptics, initial encounter
Fs: 10000 – Adverse effect of other antipsychotics and neuroleptics, initial encounter
Fs: 10000 – Adverse effect of unspecified psychostimulants, initial encounter
Fs: 10000 – Adverse effect of caffeine, initial encounter
Fs: 10000 – Adverse effect of amphetamines, initial encounter
Fs: 10000 – Adverse effect of methylphenidate, initial encounter
Fs: 10000 – Adverse effect of other psychostimulants, initial encounter
Fs: 10000 – Adverse effect of other psychotropic drugs, initial encounter
Fs: 10000 – Adverse effect of unspecified psychotropic drug, initial encounter
Fs: 10000 – Adverse effect of anticholinesterase agents, initial encounter
Fs: 10000 – Adverse effect of other parasympathomimetics [cholinergics], initial encounter
Fs: 10000 – Adverse effect of ganglionic blocking drugs, initial encounter
Fs: 10000 – Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
Fs: 10000 – Adverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter
Fs: 10000 – Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter
Fs: 10000 – Adverse effect of alpha-adrenoreceptor antagonists, initial encounter
Fs: 10000 – Adverse effect of beta-adrenoreceptor antagonists, initial encounter
Fs: 10000 – Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
Fs: 10000 – Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, initial encounter
Fs: 10000 – Adverse effect of antiallergic and antiemetic drugs, initial encounter
Fs: 10000 – Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter
Fs: 10000 – Adverse effect of vitamins, initial encounter
Fs: 10000 – Adverse effect of enzymes, initial encounter
Fs: 10000 – Adverse effect of iron and its compounds, initial encounter
Fs: 10000 – Adverse effect of anticoagulants, initial encounter
Fs: 10000 – Adverse effect of antithrombotic drugs, initial encounter
Fs: 10000 – Adverse effect of unspecified fibrinolysis-affecting drugs, initial encounter
Fs: 10000 – Adverse effect of thrombolytic drugs, initial encounter
Fs: 10000 – Adverse effect of hemostatic drug, initial encounter
Fs: 10000 – Adverse effect of other fibrinolysis-affecting drugs, initial encounter
Fs: 10000 – Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, initial encounter
Fs: 10000 – Adverse effect of other primarily systemic and hematological agents, initial encounter
Fs: 10000 – Adverse effect of unspecified primarily systemic and hematological agent, initial encounter
Fs: 10000 – Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter
Fs: 10000 – Adverse effect of calcium-channel blockers, initial encounter
Fs: 10000 – Adverse effect of other antidysrhythmic drugs, initial encounter
Fs: 10000 – Adverse effect of coronary vasodilators, initial encounter
Fs: 10000 – Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter
Fs: 10000 – Adverse effect of other antihypertensive drugs, initial encounter
Fs: 10000 – Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter
Fs: 10000 – Adverse effect of peripheral vasodilators, initial encounter
Fs: 10000 – Adverse effect of antivaricose drugs, including sclerosing agents, initial encounter
Fs: 10000 – Adverse effect of unspecified agents primarily affecting the cardiovascular system, initial encounter
Fs: 10000 – Adverse effect of other agents primarily affecting the cardiovascular system, initial encounter
Fs: 10000 – Adverse effect of histamine H2-receptor blockers, initial encounter
Fs: 10000 – Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter
Fs: 10000 – Adverse effect of stimulant laxatives, initial encounter
Fs: 10000 – Adverse effect of saline and osmotic laxatives, initial encounter
Fs: 10000 – Adverse effect of other laxatives, initial encounter
Fs: 10000 – Adverse effect of digestants, initial encounter
Fs: 10000 – Adverse effect of antidiarrheal drugs, initial encounter
Fs: 10000 – Adverse effect of emetics, initial encounter
Fs: 10000 – Adverse effect of other agents primarily affecting gastrointestinal system, initial encounter
Fs: 10000 – Adverse effect of unspecified agents primarily affecting the gastrointestinal system, initial encounter
Fs: 10000 – Adverse effect of oxytocic drugs, initial encounter
Fs: 10000 – Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter
Fs: 10000 – Adverse effect of unspecified drugs acting on muscles, initial encounter
Fs: 10000 – Adverse effect of other drugs acting on muscles, initial encounter
Fs: 10000 – Adverse effect of antitussives, initial encounter
Fs: 10000 – Adverse effect of expectorants, initial encounter
Fs: 10000 – Adverse effect of other anti-common-cold drugs, initial encounter
Fs: 10000 – Adverse effect of antiasthmatics, initial encounter
Fs: 10000 – Adverse effect of unspecified agents primarily acting on the respiratory system, initial encounter
Fs: 10000 – Adverse effect of other agents primarily acting on the respiratory system, initial encounter
Fs: 10000 – Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, initial encounter
Fs: 10000 – Adverse effect of antipruritics, initial encounter
Fs: 10000 – Adverse effect of local astringents and local detergents, initial encounter
Fs: 10000 – Adverse effect of emollients, demulcents and protectants, initial encounter
Fs: 10000 – Adverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, initial encounter
Fs: 10000 – Adverse effect of ophthalmological drugs and preparations, initial encounter
Fs: 10000 – Adverse effect of otorhinolaryngological drugs and preparations, initial encounter
Fs: 10000 – Adverse effect of dental drugs, topically applied, initial encounter
Fs: 10000 – Adverse effect of other topical agents, initial encounter
Fs: 10000 – Adverse effect of unspecified topical agent, initial encounter
Fs: 10000 – Adverse effect of mineralocorticoids and their antagonists, initial encounter
Fs: 10000 – Adverse effect of loop [high-ceiling] diuretics, initial encounter
Fs: 10000 – Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter
Fs: 10000 – Adverse effect of electrolytic, caloric and water-balance agents, initial encounter
Fs: 10000 – Adverse effect of drugs affecting uric acid metabolism, initial encounter
Fs: 10000 – Adverse effect of appetite depressants, initial encounter
Fs: 10000 – Adverse effect of antidotes and chelating agents, initial encounter
Fs: 10000 – Adverse effect of analeptics and opioid receptor antagonists, initial encounter
Fs: 10000 – Adverse effect of diagnostic agents, initial encounter
Fs: 10000 – Adverse effect of other drugs, medicaments and biological substances, initial encounter
Fs: 10000 – Adverse effect of pertussis vaccine, including combinations with a pertussis component, initial encounter
Fs: 10000 – Adverse effect of mixed bacterial vaccines without a pertussis component, initial encounter
Fs: 10000 – Adverse effect of other bacterial vaccines, initial encounter
Fs: 10000 – Adverse effect of smallpox vaccines, initial encounter
Fs: 10000 – Adverse effect of other viral vaccines, initial encounter
Fs: 10000 – Adverse effect of immunoglobulin, initial encounter
Fs: 10000 – Adverse effect of other vaccines and biological substances, initial encounter

Sibling Codes

Unspecified adverse effect of unspecified drug, medicinal and biological substance
Arthus phenomenon
Unspecified adverse effect of anesthesia
Unspecified adverse effect of insulin
Failed moderate sedation during procedure
Other drug allergy
Unspecified adverse effect of other drug, medicinal and biological substance

Parent Sibling Codes

Other anaphylactic reaction
Angioneurotic edema, not elsewhere classified
Allergy, unspecified, not elsewhere classified
Shock due to anesthesia, not elsewhere classified
Other adverse food reactions, not elsewhere classified